title: Haploidentical transplantation in patients with acquired aplastic anemia.
abstract: Haploidentical SCT (haplo-SCT) has been considered a therapeutic option in patients with acquired severe aplastic anemia (SAA) failing at least one course of immune suppressive therapy with antithymocyte globulin and lacking an HLA-matched related or unrelated donor. The platforms of both ex vivo T-cell-depleted and unmanipulated grafts have been explored in children and adults. Overall, the primary objective of a stable haploidentical hematopoietic engraftment with a low rate of GVHD is unmet in a significant proportion of patients undergoing haplo-SCT for SAA. Haploidentical transplants for refractory SAA should be performed in a specialist center with major experience in hematopoietic SCT procedures and preferably performed within the framework of a local clinical protocol designed specifically to address the prevention of graft rejection and GVHD.
authors.affiliation: Hematology and BMT Unit, EBMT CIC 813, San Raffaele Scientific Institute, Milano, Italy. ciceri.fabio@hsr.it
authors.forename: F
authors.initials: F
authors.lastname: Ciceri
authors.forename: M T
authors.initials: MT
authors.lastname: Lupo-Stanghellini
authors.forename: E T
authors.initials: ET
authors.lastname: Korthof
mesh_terms: D000741:Anemia, Aplastic / Q000601:surgery*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans